FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913441451> ?p ?o ?g. }

• W2913441451 endingPage "868" @default.
• W2913441451 startingPage "857" @default.
• W2913441451 abstract "We analyzed the predictive potential of pretreatment soluble carbonic anhydrase IX levels (sCAIX) for the efficacy of bevacizumab in the phase III neoadjuvant GeparQuinto trial. sCAIX was determined by enzyme‐linked immunosorbent assay (ELISA). Correlations between sCAIX and pathological complete response (pCR), disease‐free and overall survival (DFS, OS) were assessed with logistic and Cox proportional hazard regression models using bootstrapping for robust estimates and internal validation. 1,160 HER2‐negative patient sera were analyzed, of whom 577 received bevacizumab. Patients with low pretreatment sCAIX had decreased pCR rates (12.1 vs . 20.1%, p = 0.012) and poorer DFS (adjusted 5‐year DFS 71.4 vs . 80.5 months, p = 0.010) compared to patients with high sCAIX when treated with neoadjuvant chemotherapy (NCT). For patients with low sCAIX, pCR rates significantly improved upon addition of bevacizumab to NCT (12.1 vs . 20.4%; p = 0.017), which was not the case in patients with high sCAIX (20.1% for NCT vs . 17.0% for NCT‐B, p = 0.913). When analyzing DFS we found that bevacizumab improved 5‐year DFS for patients with low sCAIX numerically but not significantly (71.4 vs . 78.5 months; log rank 0.234). In contrast, addition of bevacizumab worsened 5‐year DFS for patients with high sCAIX (81 vs . 73.6 months, log‐rank 0.025). By assessing sCAIX levels we identified a patient cohort in breast cancer that is potentially undertreated with NCT alone. Bevacizumab improved pCR rates in this group, suggesting sCAIX is a predictive biomarker for bevacizumab with regards to treatment response. Our data also show that bevacizumab is not beneficial in patients with high sCAIX." @default.
• W2913441451 created "2019-02-21" @default.
• W2913441451 creator A5002071285 @default.
• W2913441451 creator A5003405177 @default.
• W2913441451 creator A5008649645 @default.
• W2913441451 creator A5010459872 @default.
• W2913441451 creator A5011410319 @default.
• W2913441451 creator A5011609406 @default.
• W2913441451 creator A5017728105 @default.
• W2913441451 creator A5017975237 @default.
• W2913441451 creator A5019206176 @default.
• W2913441451 creator A5021367756 @default.
• W2913441451 creator A5022181207 @default.
• W2913441451 creator A5022758199 @default.
• W2913441451 creator A5024589782 @default.
• W2913441451 creator A5032626301 @default.
• W2913441451 creator A5033698551 @default.
• W2913441451 creator A5034420549 @default.
• W2913441451 creator A5036502346 @default.
• W2913441451 creator A5041263791 @default.
• W2913441451 creator A5048105827 @default.
• W2913441451 creator A5052512508 @default.
• W2913441451 creator A5053845865 @default.
• W2913441451 creator A5054877901 @default.
• W2913441451 creator A5072762948 @default.
• W2913441451 creator A5078383767 @default.
• W2913441451 creator A5085341927 @default.
• W2913441451 creator A5086791040 @default.
• W2913441451 creator A5087559224 @default.
• W2913441451 creator A5088637879 @default.
• W2913441451 date "2019-03-04" @default.
• W2913441451 modified "2023-10-01" @default.
• W2913441451 title "Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial" @default.
• W2913441451 cites W1534401608 @default.
• W2913441451 cites W1672620526 @default.
• W2913441451 cites W1962692964 @default.
• W2913441451 cites W1984924483 @default.
• W2913441451 cites W1990923495 @default.
• W2913441451 cites W1991418795 @default.
• W2913441451 cites W2003112634 @default.
• W2913441451 cites W2005973718 @default.
• W2913441451 cites W2012288070 @default.
• W2913441451 cites W2012497832 @default.
• W2913441451 cites W2014339619 @default.
• W2913441451 cites W2016569548 @default.
• W2913441451 cites W2032947646 @default.
• W2913441451 cites W2032995169 @default.
• W2913441451 cites W2039722097 @default.
• W2913441451 cites W2042075770 @default.
• W2913441451 cites W2043506695 @default.
• W2913441451 cites W2047521631 @default.
• W2913441451 cites W2053074390 @default.
• W2913441451 cites W2061526396 @default.
• W2913441451 cites W2074932800 @default.
• W2913441451 cites W2076069507 @default.
• W2913441451 cites W2077635615 @default.
• W2913441451 cites W2081853637 @default.
• W2913441451 cites W2095545927 @default.
• W2913441451 cites W2095704084 @default.
• W2913441451 cites W2096745115 @default.
• W2913441451 cites W2097105468 @default.
• W2913441451 cites W2103563357 @default.
• W2913441451 cites W2107888799 @default.
• W2913441451 cites W2108950512 @default.
• W2913441451 cites W2111391096 @default.
• W2913441451 cites W2122574381 @default.
• W2913441451 cites W2126275851 @default.
• W2913441451 cites W2127395702 @default.
• W2913441451 cites W2135400147 @default.
• W2913441451 cites W2136091397 @default.
• W2913441451 cites W2147415463 @default.
• W2913441451 cites W2150654884 @default.
• W2913441451 cites W2153476503 @default.
• W2913441451 cites W2153982924 @default.
• W2913441451 cites W2155332617 @default.
• W2913441451 cites W2164777416 @default.
• W2913441451 cites W2167224460 @default.
• W2913441451 cites W2272689885 @default.
• W2913441451 cites W2292285564 @default.
• W2913441451 cites W2301818336 @default.
• W2913441451 cites W2315467300 @default.
• W2913441451 cites W2416232859 @default.
• W2913441451 cites W2472190236 @default.
• W2913441451 cites W2547100318 @default.
• W2913441451 cites W2612557208 @default.
• W2913441451 doi "https://doi.org/10.1002/ijc.32163" @default.
• W2913441451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30694523" @default.
• W2913441451 hasPublicationYear "2019" @default.
• W2913441451 type Work @default.
• W2913441451 sameAs 2913441451 @default.
• W2913441451 citedByCount "12" @default.
• W2913441451 countsByYear W29134414512019 @default.
• W2913441451 countsByYear W29134414512020 @default.
• W2913441451 countsByYear W29134414512021 @default.
• W2913441451 countsByYear W29134414512022 @default.
• W2913441451 countsByYear W29134414512023 @default.
• W2913441451 crossrefType "journal-article" @default.
• W2913441451 hasAuthorship W2913441451A5002071285 @default.

• next